Abstract
Purpose :
The purpose of this study was to evaluate the change of the lesion on OCTA following treatment in patients
with polypoidal choroidal vasculopathy (PCV)
Methods :
Retrospective medical record was reviewed in 16 eyes with treatment-naïve PCV, seen at Kyunghee University
Hospital between May 2016 and January 2017. All patients underwent ophthalmic examination such as ICGA,
OCT, OCTA and fundus photography. Patients diagnosed with PCV were treated with monotherapy (Intravitreal
ranibizumab or aflibercept injection) or combination therapy (Photodynamic therapy and intravitreal
ranibizumab injection). PDT was performed only in the polyp region, not containing BVN. The ratio of polyp
regression and recurrence were analyzed
Results :
Sixteen eyes of 16 patients (11 male, 5 female) were included in the study. Average age was 68.43±9.07 years.
The number of each treatment were 11 eyes for monotherapy and 5 eyes for combination therapy. At baseline,
the polypoidal lesions detected in ICGA were found in 11 eyes (69%) by OCTA, of which hypoflow halo form
was in 4 eyes (25%) and hyperflow form was in 7 eyes (44%). The BVN were detected in 7 eyes (44%) by
ICGA and in 12 eyes (75%) by OCTA. Among the 7 eyes of hyperflow that cleary showed the appearance of
polyp on OCTA, the decrease of size and disappearance of polypoidal lesion in 6 months after therapy was
detected respectively in 3 eyes (43%) and in 3 eyes (43%). The decrease of size of BVN in 6 months after
therapy was detected in 8 eyes (67%). The recurrence of polypoidal lesion and BVN in 6 months after therapy
was detected each in 1 eyes (14%) and in 4 eyes (33%). Of the 4 eyes with recurrence of BVN, 3 eyes were
recurred within 2 months after 3 consecutive monotherapy and 1 eye was recurred at 4 months after
combination therapy and additional 2 consecutive intravitreal injection
Conclusions :
Combination therapy was noted for high rate of regression of polyp and mono therapy was significantly better than combination therapy in regression of BVN
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.